Entity

Time filter

Source Type

Marseille, France

Ciccolini J.,SMARTc Pharmacokinetics Unit | Fanciullino R.,SMARTc Pharmacokinetics Unit | Serdjebi C.,Center Antoine Lacassagne | Milano G.,Center Antoine Lacassagne
Expert Opinion on Drug Metabolism and Toxicology | Year: 2014

Introduction: Breast cancer has benefited from a number of innovative therapeutics over the last decade. Cytotoxics, hormone therapy, targeted therapies and biologics can now be given to ensure optimal management of patients. As life expectancy of breast cancer patients has been significantly stretched and that several lines of treatment are now made available, determining the best drug or drug combinations to be primarily given and the best dosing and scheduling for each patient is critical for ensuring an optimal toxicity/efficacy balance.Areas covered: Defining patient's characteristics at the tumor level (pharmacogenomics) and the constitutional level (pharmacogenetics) is a rising trend in oncology. This review covers the latest strategies based upon the search of relevant biomarkers for efficacy, resistance and toxicity to be undertaken at the bedside to shift towards precision medicine in breast cancer patients.Expert opinion: In the expanding era of bioguided medicine, identifying relevant and clinically validated biomarkers from the plethora of published material remains an uneasy task. Sorting the variety of genetic and molecular markers that have been investigated over the last decade on their level of evidence and addressing the issue of drug exposure should help to improve the management of breast cancer therapy. © 2015 Informa UK, Ltd. Source

Discover hidden collaborations